PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
Cannabis$61.304.1%-38.7%TLRY 24,936TLRY 7.5%HITI -0.704%
EV$60.004%-40.0%GOEV 13,969RIDE 10.989%DCRD 0%
Gene Therapy$58.104%-41.9%BLUE 8,320VYGR 15.69%AGTC -3.91%
MedDevices$168.902.9%68.9%ATRS 5,230STIM 21.849%ADMP -11.606%
MedDiagnostics$88.203%-11.8%TTOO 43,728QTRX 29.156%ANIX -11.509%
Solar$101.603.3%1.6%HYSR 8,723ISUN 15.196%NOVA -0.954%
Uranium$88.906.1%-11.1%UEC 9,703UROY 8.889%PALAF 1.585%
Vaccines & Cell Therapy$182.501.7%82.5%SIGA 9,798ATHX 14.789%IBIO -32.279%
Web 3.0$44.005.1%-56.0%MARA 19,880MARA 10.942%FTFT -1.626%

FedEx announced earnings per share of $3.44 on revenue of $23.2B. Analysts polled by Investing.com anticipated EPS of $2.80 on revenue of $23.78B. FedEx shares…
[Read More]

Prism Daily

CytoSorbents (CTSO) Rises Almost 16% As They Receive Certification for Manufacturing

CytoSorbents (CTSO) shot up almost 16% as they announced that they just received ISO 13485 certification for its manufacturing facility in New Jersey. This achievement paves the way  for full manufacturing of CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® from this site, with…

Athersys (ATHX) Skyrockets Almost 40%, Announcing Amended Securities Purchase Agreement

Athersys (ATHX) skyrocketed 39% for the day, on news of an amended Securities Purchase Agreement to a previously closed stock and warrants offering. According to management, the Company now has more financial flexibility. The deal includes terms to extend the…

Adamis Pharma (ADMP) Plunges 28% As Covid Drug Candidate Shows No Efficacy

Adamis Pharma (ADMP) fell 28% on news of their clinical trial. Adamis released interim analysis of their Phase 2/3 trial of Tempol in high-risk subjects with Covid-19. The trial did not meet its primary endpoint, and based on the recommendation…

CEO3in60 VIDEOS

CEO3in60 Logo

Learn About Tomorrow’s Leading Companies Straight From The Source

The modern investor needs trusted, relevant information, delivered quickly and concisely. CEO3in60 provides a platform for management to succinctly share their company’s value proposition in their own words. We take the CEOs of the most dynamic up and coming companies and put them in front of the camera to provide you with the top three reasons why you should be paying attention to their business, all in less than sixty seconds.

Asensus Surgical

Asensus Surgical (NYSE American: ASXC) is leading the digital surgical market with Performance-Guided Surgery™, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence and machine learning. Shameze Rampertab, Chief Financial Officer at Asensus, outlines three value drivers for investors that will have the market paying attention in the coming months.

Soligenix

Soligenix (NASDAQ: SNGX) is developing and commercializing products to treat rare diseases in oncology and dermatology where there is an unmet medical need. Chris Schaber, President and CEO of Soligenix, Inc. spends one minute outlining three value drivers that will have investors

Read more about Soligenix, Inc.

This Week's Feature

electronic blood pressure meter and red heart

Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields “Remarkable” Results

Lexaria Bioscience (Nasdaq: LEXX) (Nasdaq: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers an alternative to traditional cannabidiol (CBD) dosing methods, enabling improved and more rapid absorption of drugs into the bloodstream and brain.

There is currently only one FDA approved CBD drug available on the market, used to treat pediatric epilepsy. Lexaria is positioned to potentially deliver the second-ever FDA approved CBD therapeutic, which has the potential to be life-changing for those living with hypertension.

Hypertension is a serious public health issue. Over 116 million Americans, and more than a billion adults worldwide, are living with high blood pressure, a major cause of premature death. However, as hypertension diagnosis numbers continue to climb, there has been a marked slowing of research and development for novel hypertension drugs.

We spoke with Professor Philip Ainslie, PhD, Lead Investigator in Lexaria’s human hypertension studies, to find out more about how Lexaria is working to develop a best-in-class delivery method for hypertension drugs.

(more…)

Traders Lens

$BTC on the weekly chart is showing signs of a renewed move downward.

$BTC on the weekly chart is showing signs of a renewed move downward.  If we do not mount a rally this week, form suggests a move back down through the recent lows around $18,000 and maybe then a retest of long term support at around $10,000.

[More Traders Lens]

Prism View

Soligenix’s Thermostable Filovirus Vaccine Program Has Potential For Global Impact

Company’s ThermoVax® platform has demonstrated protection against potentially lethal Ebola viruses Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharma company focused on developing and commercializing products to treat rare diseases continues work on its vital vaccine development program as a new…

Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields “Remarkable” Results

Lexaria Bioscience (Nasdaq: LEXX) (Nasdaq: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers an alternative to traditional cannabidiol (CBD) dosing methods, enabling improved and more rapid absorption of…

SPCB Shares Rise 62% on $33 Million National Electronic Monitoring Contract in EU

SPCB Shares Rise 62% on $33 Million National Electronic Monitoring Contract in EU With news that SuperCom (NASDAQ: SPCB), a global provider of secured solutions for e-Government, IoT and cybersecurity, was awarded the largest electronic monitoring contract in Europe this…

Quoin Pharmaceuticals: Clear Clinical Path Forward for Lead Product Candidate in Europe

Following the receipt of Scientific Advice from the European Medicines Agency (EMA), specialty pharmaceutical company, Quoin…

Soligenix Shares Surge 25% as JAMA Dermatology Publishes Phase 3 Study Findings

After publishing the results of a recent study evaluating its HyBryte™ treatment for early-stage cutaneous T-cell…

Virios’ Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results

With the aim of improving the standard of care for the 10 million Americans living with…

ProMIS Neurosciences Soars on First Nasdaq Trading Day

Newly uplisted biotech, ProMIS Neurosciences (Nasdaq: PMN)(TSX: PMN), soared on its first day of trading on…